Stephanie Parker Palmer

Cooley advised Immatics, a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, on its strategic collaboration with Moderna.

Cooley advised Immatics, a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, on its license, development and commercialization agreement with Bristol Myers Squibb for its TCR bispecific candidate, IMA401. Lawyers Ken Krisko, Carly Robinson, Brian Stalter and Stephanie Palmer led the Cooley team advising Immatics.

Hansa biopharma in its license collaboration with Sarepta Therapeutics to develop and promote imlifidase, an antibody-cleaving enzyme, for use as a pre-treatment to enable Sarepta’s AAV gene therapy to be administered for patients with Duchenne muscular dystrophy (DMD) and Limb-girdle muscular dystrophy (LGMD) who may otherwise not be eligible for treatment.

Under the terms of the agreement, Hansa will receive an upfront payment of $10 million and is eligible for additional development, regulatory and sales milestone payments potentially totaling up to $397.5 million. Hansa will book all sales of imlifidase and will earn tiered royalties up to the mid-teens on any incremental gene therapy sales that arise from treating antibody-positive patients enabled through imlifidase pre-treatment.

Cooley advised Therachon Holding, a clinical-stage biotechnology company focused on rare diseases, in its agreement to sell to Pfizer, an innovative biopharmaceutical company discovering, developing and providing medicines, vaccines and consumer healthcare products, for up to $810 million. Partners Ryan Sansom and Michal Berkner led the Cooley team. 

Cooley advised Avidity Biosciences, Inc., a privately-held biotech company pioneering Antibody Oligonucleotide Conjugates (AOC™), on its global licensing and research collaboration with Eli Lilly focused on the discovery, development and commercialization of potential new medicines in immunology and other select indications for up to $440 million with $35 million upfront.